MedTrace Logo

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-02-11

No results posted yet for this study

Summary

The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of \>6 months and \<10 years, HbA1c \<10%) to evaluate its effects on the peripheral autonomic nervous system, as well as inflammatory markers, and measures of oxidative and nitrosative stress.

Conditions

  • Autonomic Nervous System Diseases
  • Sweat Gland Diseases
  • Diabetic Neuropathy With Neurologic Complication

Interventions

DRUG

Liraglutide 6 mg Solution for Injection

OTHER

Placebo

Sponsors & Collaborators

  • Eastern Virginia Medical School

    lead OTHER

Principal Investigators

  • Aaron Vinik, MD, PhD · Eastern Virginia Medical School

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-04-30
Completion
2020-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426085 on ClinicalTrials.gov